We are live on ! Find out more

974 hedge funds and large institutions have $85.6B invested in Biogen in 2015 Q2 according to their latest regulatory filings, with 100 funds opening new positions, 367 increasing their positions, 348 reducing their positions, and 85 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more first-time investments, than exits

New positions opened: 100 | Existing positions closed: 85

5% more repeat investments, than reductions

Existing positions increased: 367 | Existing positions reduced: 348

1% more funds holding

Funds holding: 967974 (+7)

5% less capital invested

Capital invested by funds: $90.2B → $85.6B (-$4.63B)

24% less funds holding in top 10

Funds holding in top 10: 6852 (-16)

30% less call options, than puts

Call options by funds: $1.21B | Put options by funds: $1.72B

Holders
974
Holders Change
+7
Holders Change %
+0.72%
% of All Funds
26.11%
Holding in Top 10
52
Holding in Top 10 Change
-16
Holding in Top 10 Change %
-23.53%
% of All Funds
1.39%
New
100
Increased
367
Reduced
348
Closed
85
Calls
$1.21B
Puts
$1.72B
Net Calls
-$507M
Net Calls Change
+$74.4M

BIIB Hedge Fund Activity: Q2 2015 in Review

974 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2015, worth a combined $85.6B — down 5.1% from $90.2B a quarter earlier.

Buyers outnumbered sellers: 100 funds opened new BIIB positions and 85 closed out — a net gain of 15 holders — while 367 added to existing stakes and 348 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $549M. The largest seller was JP Morgan Chase, cutting an estimated $358M.

  • 974 institutional investors held Biogen (BIIB) as of Q2 2015, up from 967 in Q1 2015.
  • Funds reported $85.6B of Biogen stock for Q2 2015, down 5.1% quarter-over-quarter.
  • 100 funds opened new Biogen positions in Q2 2015 and 85 closed out, a net change of +15 holders.
  • The largest Biogen buyer in Q2 2015 was Wellington Management Group, an estimated $549M added.
  • The largest Biogen seller in Q2 2015 was JP Morgan Chase, an estimated $358M sold.

Based on aggregated 13F filings for Q2 2015.